Cancer Research and Treatment

Original Article

Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy: Seung Tae Kim, Kyong Hwa Park, Jun Suk Kim, Sang Won Shin, Yeul Hong Kim; Cancer Res Treat. 2013;45(1):55-62. Published online March 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.1.55

PURPOSE
Activating mutation of the KRAS oncogene is an established negative predictor for anti-epidermal growth factor receptor (anti-EGFR) therapies in metastatic colorectal cancer (CRC). However, KRAS mutation as a prognostic factor of survival outcome remains controversial in CRC, independent of anti-EGFR therapies.
MATERIALS AND METHODS
We conducted a retrospective analysis of 103 CRC patients who were available for evaluation of KRAS mutation status. None of the patients analyzed had received anti-EGFR therapies. The role of KRAS mutation status was evaluated as a predictive factor for oxaliplatin or irinotecan and as a prognostic factor in CRC patients who did not receive anti-EGFR therapies.
RESULTS
Mutations in KRAS were observed in 48.5% of patients. The response for oxaliplatin- (p=0.664) and irinotecan-based (p=0.255) cytotoxic chemotherapy did not differ according to the KRAS mutation status. In addition, no significant difference in progression free survival (PFS; oxaliplatin, p=0.583 and irinotecan, p=0.426) and overall survival (OS; p=0.258) was observed between the wild and mutant type of the KRAS gene. In univariate and multivariate analyses, KRAS mutations did not have a major prognostic value regarding PFS (oxaliplatin: hazard ratio, 0.892; 95% confidence interval [CI], 0.590 to 1.347; p=0.586 and irinotecan: hazard ratio, 0.831; 95% CI, 0.524 to 1.319; p=0.433) or OS (hazard ratio, 0.754; 95% CI, 0.460 to 1.236; p=0.263). In addition, anti-vascular endothelial growth factor therapies did not affect PFS to oxaliplatin or irinotecan and OS.
CONCLUSION
KRAS mutation is not a prognostic marker for PFS to oxaliplatin or irinotecan and OS in CRC patients who did not receive anti-EGFR therapies.

Citations

Citations to this article as recorded by

The Landscape of PIK3CA Mutations in Colorectal Cancer
Ioannis A. Voutsadakis
Clinical Colorectal Cancer.2021; 20(3): 201. CrossRef
Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives
Gianluca Pellino, Gaetano Gallo, Pierlorenzo Pallante, Raffaella Capasso, Alfonso De Stefano, Isacco Maretto, Umberto Malapelle, Shengyang Qiu, Stella Nikolaou, Andrea Barina, Giuseppe Clerico, Alfonso Reginelli, Antonio Giuliani, Guido Sciaudone, Christo
Gastroenterology Research and Practice.2018; 2018: 1. CrossRef
Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90
Michael J. Magnetta, Anish Ghodadra, Steven J. Lahti, Minzhi Xing, Di Zhang, Hyun S. Kim
Abdominal Radiology.2017; 42(2): 451. CrossRef
C1QBP is upregulated in colon cancer and binds to apolipoprotein A-I
Kun Kim, Min-Jeong Kim, Kyung-Hee Kim, Sun-A Ahn, Jong Heon Kim, Jae Youl Cho, Seung-Gu Yeo
Experimental and Therapeutic Medicine.2017; 13(5): 2493. CrossRef
Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis
Javier Garde Noguera, Eloisa Jantus-Lewintre, Mireia Gil-Raga, Elena Evgenyeva, Sonia Maciá Escalante, Antonio Llombart-Cussac, Carlos Camps Herrero
Molecular and Clinical Oncology.2017; 6(3): 403. CrossRef
Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases
Hiroaki Niitsu, Takao Hinoi, Manabu Shimomura, Hiroyuki Egi, Minoru Hattori, Yasuyo Ishizaki, Tomohiro Adachi, Yasufumi Saito, Masashi Miguchi, Hiroyuki Sawada, Masatoshi Kochi, Shoichiro Mukai, Hideki Ohdan
World Journal of Surgical Oncology.2015;[Epub] CrossRef
KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases
Steven J. Lahti, Minzhi Xing, Di Zhang, James J. Lee, Michael J. Magnetta, Hyun S. Kim
Journal of Vascular and Interventional Radiology.2015; 26(8): 1102. CrossRef
Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer
LEE CHENG PHUA, HUI WEN NG, ANGIE HUI LING YEO, ELYA CHEN, MICHELLE SHU MEI LO, PEH YEAN CHEAH, ERIC CHUN YONG CHAN, POH KOON KOH, HAN KIAT HO
Oncology Letters.2015; 10(4): 2519. CrossRef
Characterization of rare transformingKRASmutations in sporadic colorectal cancer
Joanna HM Tong, Raymond WM Lung, Frankie MC Sin, Peggy PY Law, Wei Kang, Anthony WH Chan, Brigette BY Ma, Tony WC Mak, Simon SM Ng, Ka Fai To
Cancer Biology & Therapy.2014; 15(6): 768. CrossRef
Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
Alfonso De Stefano
World Journal of Gastroenterology.2014; 20(29): 9732. CrossRef
RAS mutations: impact on treatment outcome
Sameh Mikhail, Tanios Bekaii-Saab
Colorectal Cancer.2013; 2(6): 525. CrossRef
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
Ching-Wen Huang, Hsiang-Lin Tsai, Yi-Ting Chen, Chun-Ming Huang, Cheng-Jen Ma, Chien-Yu Lu, Chao-Hung Kuo, Deng-Chyang Wu, Chee-Yin Chai, Jaw-Yuan Wang
BMC Cancer.2013;[Epub] CrossRef

13,761 View
70 Download
12 Crossref

First
Prev
Page of 1
Next
Last

Search